Doha: The University Medical City, represented by the National Center for the Treatment of Blood Diseases and Bone Marrow Transplantation, has successfully implemented the first Chimeric Antigen Receptor T-cell (CAR-T) therapy in the Sultanate of Oman, utilizing national medical personnel and international partnerships.

According to Qatar News Agency, this achievement marks a pioneering medical milestone, positioning Oman among regional leaders in providing advanced and precision treatments for blood cancer patients. CAR-T cell therapy is one of the latest immunotherapies, where T-cells are extracted from the patient, genetically modified, and then reinfused to precisely target cancer cells.

The treatment has shown remarkable response rates in patients with B-cell Acute Lymphoblastic Leukemia (B-ALL) and Diffuse Large B-cell Lymphoma (DLBCL), particularly for those unresponsive to conventional therapies.